Management of Advanced-Stage and Recurrent Endometrial Cancer

Seminars in Oncology

Volumn 36, Issue 2, 2009, Pages 145-154

  Ray, Mandira ^a   Fleming, Gini ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; EVENING DOSAGE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; LYMPH NODE DISSECTION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SEPSIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 62949201676     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.12.006     Document Type: Article

References (72)

1. Weiss N.S., Szekely D.R., and Austin D.F. Increasing incidence of endometrial cancer in the United States. N Engl J Med 294 (1976) 1259-1262
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P., et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83 Suppl 1 (2003) 79-118
4. Kong A., Simera I., Collingwood M., Williams C., and Kitchener H. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 18 (2007) 1595-1604
5. Clement P.B., and Young R.H. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9 (2002) 145-184
6. Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 46 (2007) 26-32
7. Umpierre S.A., Burke T.W., Tornos C., Ordonez N., Levenback C., and Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 13 (1994) 127-130
8. Matthews R.P., Hutchinson-Colas J., Maiman M., Fruchter R.G., Gates E.J., Gibbon D., et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 65 (1997) 206-212
9. Trope C., Kristensen G.B., and Abeler V.M. Clear-cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynaecol 15 (2001) 433-446
10. Cirisano Jr. F.D., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74 (1999) 385-394
11. Deligdisch L., Kase N.G., and Bleiweiss I.J. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 46 (2000) 17-21
12. Abeler V.M., and Kjorstad K.E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 40 (1991) 207-217
13. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999) 1736-1744
14. Singh M., Zaino R.J., Filiaci V.J., and Leslie K.K. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 106 (2007) 325-333
15. Calero F., Asins-Codoner E., Jimeno J., Rodriguez Escudero F., Mendana J., Iglesias J., et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 27 (1991) 864-866
16. Thigpen J.T., Buchsbaum H.J., Mangan C., and Blessing J.A. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 63 (1979) 21-27
17. Trope C., Grundsell H., Johnsson J.E., and Cavallin-Stahl E. A phase II study of Cis-platinum for recurrent corpus cancer. Eur J Cancer 16 (1980) 1025-1026
18. Barton C., Buxton E.J., Blackledge G., Mould J.J., and Meanwell C.A. A phase II study of ifosfamide in endometrial cancer. Cancer Chemother Pharmacol 26 Suppl (1990) S4-S6
19. Von Hoff D.D., Green S., Alberts D.S., Stock-Novack D.L., Surwit E.A., Miller T.P., et al. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group study. Am J Clin Oncol 14 (1991) 193-194
20. Hilgers R.D., Von Hoff D.D., Stephens R.L., Boutselis J.G., and Rivkin S.E. Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group study. Cancer Treat Rep 69 (1985) 1329-1330
21. Thigpen J.T., Kronmal R., Vogel S., Hynes H.E., Nahhas W., Belt R.J., et al. A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group study. Am J Clin Oncol 10 (1987) 429-431
22. Muss H.B., Blessing J.A., Hatch K.D., Soper J.T., Webster K.D., and Kemp G.M. Methotrexate in advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 13 (1990) 61-63
23. Carbone P.P., and Carter S.K. Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol 2 (1974) 348-353
24. Woo H.L., Swenerton K.D., and Hoskins P.J. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 19 (1996) 290-291
25. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G., and Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7 (1996) 861-863
26. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
27. Homesley H.D., Blessing J.A., Sorosky J., Reid G., and Look K.Y. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 98 (2005) 294-298
28. Muggia F.M., Blessing J.A., Sorosky J., and Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 20 (2002) 2360-2364
29. Deppe G., Cohen C.J., and Bruckner H.W. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. Gynecol Oncol 10 (1980) 51-54
30. Seski J.C., Edwards C.L., Herson J., and Rutledge F.N. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 59 (1982) 225-228
31. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 33 (1989) 68-70
32. Burke T.W., Munkarah A., Kavanagh J.J., Morris M., Levenback C., Tornos C., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51 (1993) 397-400
33. van Wijk F.H., Lhomme C., Bolis G., Scotto di Palumbo V., Tumolo S., Nooij M., de Oliveira C.F., et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 39 (2003) 78-85
34. Fracasso P.M., Blessing J.A., Molpus K.L., Adler L.M., Sorosky J.I., and Rose P.G. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 103 (2006) 523-526
35. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62 (1996) 278-281
36. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 (2003) 277-281
37. Katsumata N., Noda K., Nozawa S., Kitagawa R., Nishimura R., Yamaguchi S., et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer 93 (2005) 999-1004
38. Gunthert A.R., Ackermann S., Beckmann M.W., Camara O., Kiesel L., Rensing K., et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol 104 (2007) 86-90
39. Wadler S., Levy D.E., Lincoln S.T., Soori G.S., Schink J.C., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93. J Clin Oncol 21 (2003) 2110-2114
40. Miller D.S., Blessing J.A., Lentz S.S., and Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 87 (2002) 247-251
41. Poplin E.A., Liu P.Y., Delmore J.E., Wilczynski S., Moore Jr. D.F., Potkul R.K., et al. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study. Gynecol Oncol 74 (1999) 432-435
42. Rose P.G., Blessing J.A., Lewandowski G.S., Creasman W.T., and Webster K.D. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 63 (1996) 101-104
43. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004) 2159-2166
44. du Bois A., Pfisterer J., Burchardi N., Loibl S., Huober J., Wimberger P., et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 107 (2007) 518-525
45. Gebbia V., Testa A., Borsellino N., Ferrera P., Tirrito M., and Palmeri S. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen. Ann Oncol 12 (2001) 767-772
46. Sorbe B., Andersson H., Boman K., Rosenberg P., and Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 18 (2008) 803-808
47. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., and Rodgers W.H. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 106 (2007) 16-22
48. Lewis Jr. G.C., Slack N.H., Mortel R., and Bross I.D. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 2 (1974) 368-376
49. Martin-Hirsch P.L., Lilford R.J., and Jarvis G.J. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 65 (1996) 201-207
50. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 24 (2006) 36-44
51. Maggi R., Lissoni A., Spina F., Melpignano M., Zola P., Favalli G., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95 (2006) 266-271
52. Kuoppala T., Maenpaa J., Tomas E., Puistola U., Salmi T., Grenman S., et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 110 (2008) 190-195
53. Hogberg T., Rosenberg P., Kristensen G., de Oliveira C.F., de Pont Christensen R., Sorbe B., et al. A randomized phase-III study on adjuvant treatment with radiation (RT) {+/-} chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). ASCO Meeting Abstracts 25 (2007) 5503
54. Homesley H.F., Gibbons V., Long S.K., Spirtos H.J., Morris N.M., DeGeest R.T., et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 108 (2008) S2
55. Susumu N., Sagae S., Udagawa Y., Niwa K., Kuramoto H., Satoh S., et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108 (2008) 226-233
56. Nout R.A., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial [abstract]. ASCO Meeting Abstracts 26 (2008) LBA5503
57. Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., and Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95 (2004) 593-596
58. Grushko T.A., Ridderstrale K., Olopade O.I., Mundt A., and Fleming G.F. Identification of HER-2/NEU oncogene amplification by fluorescence in situ hybridization in endometrial carcinoma from patients included in Gynecologic Oncology Group trial 177. Proc Am Soc Clin Oncol 22 (2003) abstr 1880
59. Fleming G.F., Sill M.A., Thigpen J.T., Adler L.M., Berek J.S., Di Silvestro P.A., et al. Phase II evaluation of trastuzamab in patients with advanced or recurrent endometrial cancer: a report of GOG 181B. (Abstr 1821). Proc Am Soc Clin Oncol 22 (2003) 543
60. Jasas K.V., Fyles A., Elit L., Hoskins P.J., Biagi J., Dubuc-Lissoir J., et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 (2004) 5019
61. Sood A.K., Fletcher M.S., and Hendrix M.J. The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Invest 9 (2002) 2-9
62. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57 (1997) 4736-4738
63. Yu K., Toral-Barza L., Shi C., Zhang W.G., and Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7 (2008) 307-315
64. Zhou C., Bae-Jump V.L., Whang Y.E., Gehrig P.A., and Boggess J.F. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol 101 (2006) 305-310
65. Slomovitz B.M., Wu W., Broaddus R.R., Soliman P.T., Wolf J., Sun C.C., et al. mTOR inhibition is a rational target for the treatment of endometrial cancer. J Clin Oncol (Meeting Abstracts) 22 (2004) 5076
66. Colombo N., McMeekin S., Schwartz P., Kostka J., Sessa C., Gehrig P., et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol (Meeting Abstracts) 25 (2007) 5516
67. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P., et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 6 (2001) 47-86
68. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1408-1414
69. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S., Reid G., Soper J.T., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3808-3813
70. Aapro M.S., van Wijk F.H., Bolis G., Chevallier B., van der Burg M.E., Poveda A., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 (2003) 441-448
71. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004) 3902-3908
72. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15 (2004) 1173-1178